Orbit Financial Capital acted as the exclusive sell-side advisor to Selvax for securing an Industry Partnership with Gufic Bioscience Ltd.
Gufic Bioscience Ltd picked up a minority stake in Selvax Pty Ltd and undertake mutually agreed development activities in return for the exclusive commercial rights for Selvax immunotherapy in India along with an equal share of future revenues in Europe.
Incorporated in the year 2000, Gufic Biosciences Limited is engaged in manufacture and marketing of pharmaceutical formulations in various dosage forms such as injectables, syrups, ointments, lotions etc.
About Selvax: Founded in 2014, Selvax Pty Ltd is a bio-technology company based in Perth, West Australia, which is developing a novel immunology based treatment for large solid tumours. Their “self-vaccine” technology has achieved cancer clearance rates in the range of 30% – 100% in repeated small animal studies for a range of solid tumours.